What is Zacks Research’s Forecast for Stryker Q1 Earnings?

Stryker Co. (NYSE:SYK) – Stock analysts at Zacks Research lowered their Q1 2025 earnings estimates for shares of Stryker in a report issued on Tuesday, February 18th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical technology company will post earnings of $2.77 per share for the quarter, down from their previous forecast of $2.82. The consensus estimate for Stryker’s current full-year earnings is $13.47 per share. Zacks Research also issued estimates for Stryker’s Q2 2025 earnings at $3.15 EPS, Q3 2025 earnings at $3.21 EPS, FY2025 earnings at $13.47 EPS, Q1 2026 earnings at $3.08 EPS, Q2 2026 earnings at $3.33 EPS, Q3 2026 earnings at $3.31 EPS and FY2026 earnings at $14.37 EPS.

Several other analysts have also issued reports on the stock. Citigroup upped their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. UBS Group boosted their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Stifel Nicolaus upped their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Finally, Royal Bank of Canada upped their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $422.15.

Stryker Stock Performance

Shares of SYK stock opened at $382.59 on Friday. Stryker has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $145.99 billion, a PE ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The firm has a fifty day simple moving average of $378.07 and a two-hundred day simple moving average of $368.99.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 earnings per share.

Institutional Investors Weigh In On Stryker

Several hedge funds have recently made changes to their positions in the company. Kohmann Bosshard Financial Services LLC purchased a new stake in Stryker in the fourth quarter valued at about $25,000. Dunhill Financial LLC increased its holdings in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the period. Rakuten Securities Inc. increased its holdings in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC acquired a new stake in Stryker during the fourth quarter worth about $30,000. Finally, BankPlus Trust Department acquired a new stake in Stryker during the fourth quarter worth about $33,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker’s dividend payout ratio is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.